logo-loader
viewZacks Small-Cap Research

Zacks Small-Cap Research: Biotech IPOs outperformed in 2019, talks through 2020 drivers

Zacks Small-Cap Research Senior Biotechnology Analyst John Vandermosten sat down with Proactive at the BIO CEO & Investor Conference in New York. Vandermosten says while biotech IPOs outperformed in 2019, on the horizon, some concerns loom that may affect these companies such as the deadly coronavirus, and the current political landscape.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Duke Royalty Limited 'doing just fine' by maintaining a diversified...

Duke Royalty Limited (LON:DUKE) CEO Neil Johnson tells Proactive the provider of alternative capital solutions is 'doing just fine' and withstanding the current pandemic situation by maintaining a diversified portfolio. Johnson says Duke, which recently reported a trading update, has exposure...

3 days, 11 hours ago

2 min read